Sugi Predict

Sugi Predict / Compounds / SCHEMBL6460259

SCHEMBL6460259

SCHEMBL6460259

Nc1ncnc2c1c(-c1ccc(NS(=O)(=O)c3ccc(F)cc3)c(F)c1)cn2C1CCN(Cc2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ TEK Q02763 1/20 0.56
▸ MEN1 O00255 7/20 0.53
▸ EIF2AK3 Q9NZJ5 5/20 0.52
▸ RIPK2 O43353 2/20 0.48
▸ NEK7 Q8TDX7 5/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6460401 0.87 EIF2AK3 (0.49) TEKEIF2AK3RIPK2NEK7
SCHEMBL6463833 0.87 TEK (0.56) TEKMEN1EIF2AK3RIPK2NEK7
SCHEMBL12934129 0.85 TEK (0.65) TEKMEN1RIPK2NEK7
SCHEMBL6460593 0.85 EIF2AK3 (0.58) TEKMEN1EIF2AK3RIPK2NEK7
SCHEMBL6465277 0.83 TEK (0.52) TEKMEN1EIF2AK3RIPK2NEK7
SCHEMBL6459712 0.83 TEK (0.73) TEKMEN1EIF2AK3RIPK2NEK7
SCHEMBL6465140 0.83 TEK (0.73) TEKMEN1EIF2AK3RIPK2NEK7
SCHEMBL6459716 0.83 TEK (0.73) TEKMEN1EIF2AK3RIPK2NEK7
SCHEMBL6461714 0.83 RIPK2 (0.68) TEKMEN1RIPK2
SCHEMBL12934107 0.83 TEK (0.58) TEKMEN1RIPK2NEK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 — — US claimed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 — — US claimed
CN-1335849-A Pyrrolopyrimidines as protein kinase inhibitors BASF AG (DE) 2002-02-13 — — CN claimed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 — — US disclosed
WO-2004100868-A2 METHOD OF TREATING TRANSPLANT REJECTION ABBOTT LABORATORIES (US) 2004-11-25 — — WO disclosed
US-6713474-B2 SERINE-THREONINE AND TYROSINE KINASE INHIBITORS ABBOTT GMBH & CO. KG (DE) 2004-03-30 — — US disclosed
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents ABBVIE DEUTSCHLAND GMBH & CO KG (DE) 2003-08-14 — — US disclosed
WO-2001072751-A1 PYRROLOPYRIMIDINES AS TYROSINE KINASE INHIBITORS KNOLL GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) 2001-10-04 — — WO disclosed
EP-1114053-A1 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2001-07-11 — — EP disclosed
WO-2000017203-A1 PYRROLOPYRIMIDINES AS PROTEIN KINASE INHIBITORS BASF AKTIENGESELLSCHAFT (DE) 2000-03-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN TEK 1465/4885MEN1 4582/4885EIF2AK3 3756/4885
US-20030153752-A1 Pyrrolopyrimidines as therapeutic agents FLT1, FLT4, TFPI TEK 22/4885MEN1 2108/4885EIF2AK3 928/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.